Asset profile
Sacituzumab Tirumotecan
Antibody–drug conjugate
Phase 3underway
Evidence outlook · registrational
HR+/HER2- Metastatic Breast Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2026-12-31.
Also in development:Non-Small Cell Lung Cancer · Phase 3
Featured evidence outside covered markets:NCT05347134 · Triple Negative Breast Cancer · Phase 3 · met primary endpoint · ungradedNCT06393374 · Triple-Negative Breast Cancer · Phase 3 · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
122 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication; 82 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sacituzumab Tirumotecan: this drug | Phase 3 | Antibody–drug conjugate | TROP2 | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Sacituzumab Govitecan | Approved | Antibody–drug conjugate | TROP2 | ||
| DB-1305 | Phase 2 | Antibody–drug conjugate | TROP2 | ||
| BL-M02D1 | Phase 1/2 | Antibody–drug conjugate | TROP2 | ||
| LCB84 | Phase 1/2 | Antibody–drug conjugate | TROP2 | ||
| MT-302 | Phase 1 | Small molecule | TROP2 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A |
…and 107 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(102 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
October 2026 (1)
Phase 2Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast CancerNot yet recruiting
Est. primary completion 2026-10-30 · NCT07054242 · CT.gov ↗
What to watch
November 2026 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11 · NCT06448312 · CT.gov ↗
What to watch
December 2026 (6)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07108816 · CT.gov ↗
What to watch
Phase 2Selected Subjects With Advanced Solid TumorsActive not recruiting
Est. primary completion 2026-12-30 · NCT05631262 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04152499 · CT.gov ↗
What to watch
Phase 2Adenoid Cystic Carcinoma of the Head and Neck, SBRT, Antibody-drug ConjugatesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07579598 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06081959 · CT.gov ↗
What to watch
2027 (36)
January 2027 (3)
Phase 2TNBC, Brain MetastasisRecruiting
Est. primary completion 2027-01 · NCT07623577 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting
Est. primary completion 2027-01-01 · NCT07561463 · CT.gov ↗
What to watch
Phase 3Gastroesophageal CancerActive not recruiting
Est. primary completion 2027-01-04 · NCT06356311 · CT.gov ↗
What to watch
February 2027 (2)
March 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03 · NCT06992739 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-04-15 · NCT07139470 · CT.gov ↗
What to watch
May 2027 (2)
June 2027 (4)
Phase 2Lung CancerNot yet recruiting
Est. primary completion 2027-06 · NCT07244926 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-20 · NCT07343479 · CT.gov ↗
What to watch
Phase 2Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant …Recruiting
Est. primary completion 2027-06-30 · NCT07179783 · CT.gov ↗
What to watch
July 2027 (7)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07 · NCT07071337 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT07105852 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract Cancer(BTC)Not yet recruiting
Est. primary completion 2027-07-01 · NCT07701122 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07789444 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Neoplasms (Tumours)Not yet recruiting
Est. primary completion 2027-07-20 · NCT07077564 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-30 · NCT07258108 · CT.gov ↗
What to watch
August 2027 (4)
Phase 2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-08-01 · NCT07088211 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT07329322 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07689292 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Not yet recruiting
Est. primary completion 2027-08-31 · NCT07501169 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT07703228 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Solid TumorActive not recruiting
Est. primary completion 2027-11-30 · NCT05642780 · CT.gov ↗
What to watch
December 2027 (10)
Phase 2Advanced Biliary Tract CancersNot yet recruiting
Est. primary completion 2027-12 · NCT07729033 · CT.gov ↗
What to watch
Phase 2Thymic Epithelial Tumors, Advanced Stage, Second-line TherapyNot yet recruiting
Est. primary completion 2027-12-22 · NCT07343453 · CT.gov ↗
What to watch
Phase 2Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07197008 · CT.gov ↗
What to watch
Phase 2Platinum-resistant Recurrent Ovarian Cancer (PROC)Not yet recruiting
Est. primary completion 2027-12-30 · NCT07314619 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07854509 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07702305 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06049212 · CT.gov ↗
What to watch
Phase 2Advanced Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT06849492 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Head and Neck CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07686588 · CT.gov ↗
What to watch
Early phase / not applicableAdvanced Thyroid Carcinoma, Radioiodine-refractory Differentiated Thyroid Cancer, Poorly Differentiated Thyroid CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT07068542 · CT.gov ↗
What to watch
2028 (33)
January 2028 (9)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01 · NCT07670013 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01 · NCT07109284 · CT.gov ↗
What to watch
Phase 2Ovarian Epithelial CancerActive not recruiting
Est. primary completion 2028-01 · NCT07341100 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07348861 · CT.gov ↗
What to watch
Phase 3Endometrial CancerActive not recruiting
Est. primary completion 2028-01-10 · NCT06132958 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-22 · NCT07548060 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast Cancer, PD-L1 PositiveNot yet recruiting
Est. primary completion 2028-01-30 · NCT07244874 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-02-15 · NCT07545213 · CT.gov ↗
What to watch
March 2028 (2)
April 2028 (1)
Phase 2Thymic CarcinomaRecruiting
Est. primary completion 2028-04 · NCT07324629 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2028-05-09 · NCT06445972 · CT.gov ↗
What to watch
June 2028 (4)
Phase 2Phase II, Sacituzumab, Tirumotecan, SMARCB1-deficient Renal Medullary CarcinomaRecruiting
Est. primary completion 2028-06-01 · NCT07438626 · CT.gov ↗
What to watch
Phase 3Cervical CancerActive not recruiting
Est. primary completion 2028-06-15 · NCT06459180 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT07375316 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2028-06-30 · NCT07256236 · CT.gov ↗
What to watch
August 2028 (6)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08 · NCT07371208 · CT.gov ↗
What to watch
Phase 2Metastatic Triple Negative Breast CancersNot yet recruiting
Est. primary completion 2028-08 · NCT07458113 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08 · NCT07697586 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-08-17 · NCT06305754 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC)Not yet recruiting
Est. primary completion 2028-08-31 · NCT07778368 · CT.gov ↗
What to watch
September 2028 (3)
Phase 2ESCC, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), GC/GEJCNot yet recruiting
Est. primary completion 2028-09-01 · NCT07701681 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic MSI-H/dMMR Gynecological MalignanciesNot yet recruiting
Est. primary completion 2028-09-01 · NCT07738757 · CT.gov ↗
What to watch
Phase 2HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, InetetamabRecruiting
Est. primary completion 2028-09-30 · NCT07182721 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic, Papillary Thyroid CarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07521670 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-11-30 · NCT06706219 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12 · NCT07128693 · CT.gov ↗
What to watch
Phase 2Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral NeuropathyNot yet recruiting
Est. primary completion 2028-12-01 · NCT07662863 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-01 · NCT07819578 · CT.gov ↗
What to watch
Phase 2Advanced Small Bowel AdenocarcinomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07720258 · CT.gov ↗
What to watch
2029 (12)
January 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1/2Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2029-03-14 · NCT06637423 · CT.gov ↗
What to watch
April 2029 (1)
Phase 3Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerRecruiting
Est. primary completion 2029-04-27 · NCT06824467 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2029-07-27 · NCT07419295 · CT.gov ↗
What to watch
August 2029 (2)
September 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07750704 · CT.gov ↗
What to watch
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Papillary Renal Carcinoma, Variant Histology Urothelial CarcinomaNot yet recruiting
Est. primary completion 2029-10 · NCT07716917 · CT.gov ↗
What to watch
Phase 1/2Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract CancerRecruiting
Est. primary completion 2029-10-16 · NCT06428409 · CT.gov ↗
What to watch
November 2029 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Unresectable Thymic CarcinomaNot yet recruiting
Est. primary completion 2029-12 · NCT07750353 · CT.gov ↗
What to watch
2030 (4)
March 2030 (2)
May 2030 (1)
Phase 3Triple Negative Breast NeoplasmsRecruiting
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Triple-Negative Breast CancerRecruiting
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch
2031 (2)
March 2031 (1)
Phase 2Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic, Unresectable Squamous, Cell Carcinoma of the Anus/ RectumNot yet recruiting
Est. primary completion 2031-03-01 · NCT07511023 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Cervical CancerRecruiting
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
2032 (3)
January 2032 (1)
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
February 2032 (1)
Phase 2Lung Neoplasm MalignantActive not recruiting
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
2033 (2)
February 2033 (1)
Phase 3Ovarian Neoplasms, Ovarian CancerRecruiting
Est. primary completion 2033-02-25 · NCT07318558 · CT.gov ↗
What to watch
March 2033 (1)
Phase 3Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast NeoplasmsRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
February 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch
2036 (1)
September 2036 (1)
Phase 2Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer, Recurrent Ovarian Clear Cell AdenocarcinomaRecruiting
Est. primary completion 2036-09 · NCT07718854 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.